ClinicalTrials.gg
CompletedNCT05279313Updated May 14, 2026

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

A Phase 3 interventional study of Centanafadine Hydrochloride in Attention Deficit/Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 86 sites in 3 countries. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
680
Allocation
Not applicable
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd. — 5 open to participants now, 5 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · Otsuka Holdings Co., Ltd..

Enrollment
2nd of 25
680 · median 180
Started
2022
with 2 others
Phase 3
10 of 25
3 open now
Registered
15th of 25
by date

Among the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., this one is the 2nd largest by enrollment, is one of 3 that started in 2022, is one of 10 in phase 3, and was the 15th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

To evaluate long-term safety exposure

Read the detailed description

This open-label study will assess the overall safety and tolerability of centanafadine once daily extended-release capsules in pediatric subjects (ages 4-17 years). The study will accept rollover subjects from double-blind parent trials and individuals that did not participate in one of the double-blind parent trials, may enroll as De Novo subjects after meeting all required study entry criteria. All subjects will complete a minimum of 52 weeks and may continue until all enrolled subjects within the age group the subject was in at the start of their participation in the trial (13 to 17 years; 6 to 12 years; 4 to 5 years) have had a chance to reach the Week 52 visit.

03

Conditions studied

  • Attention Deficit/Hyperactivity Disorder

Keywords

  • Centanafadine
  • ADHD
04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Rollover subjects from double-blind parent trials inclusion criteria:

  • Subjects who completed the 6-week double-blind treatment period and the 7 (+2) day follow-up in a double-blind parent trial and who, in the opinion of the investigator, could potentially benefit from centanafadine QD XR for ADHD

De novo subjects inclusion criteria:

  • Males and females aged 4 to 17 years (inclusive) at the time of /assent.
  • A primary diagnosis of ADHD based on diagnosis criteria as confirmed with the MINI KID.
  • A minimum symptoms total raw score of ≥ 28 on the ADHD-RS-5 at baseline.
  • A score of 4 or higher on the CGI-S-ADHD at baseline.
  • Subjects aged 4 or 5 years only; has failed adequate psychotherapy or in the investigator's opinion, is severe enough to require pharmacotherapy in the absence of prior psychotherapy.

Rollover subjects from double-blind parent trials exclusion criteria:

  • Subjects who, during the double-blind parent trials, experienced, in the opinion of the investigator, poor tolerability to IMP or whose safety assessments resulted in new concerns that would suggest the subject may not be appropriate for a 52-week treatment with IMP.

De novo subjects exclusion criteria:

  • A comorbid diagnosis of: Tourette's Disorder, Generalized Anxiety Disorder that is severe enough to interfere with trial procedures, Panic Disorder, Conduct Disorder, Psychosis, Post-traumatic Stress Disorder, Bipolar Disorder, Autism Spectrum Disorder, Binge Eating Disorder (adolescents only), Anorexia (adolescents only), Bulimia (adolescents only), Oppositional Defiant Disorder that is severe enough to interfere with trial conduct (allowed if it is not the primary focus of treatment), Obsessive-Compulsive Disorder that is severe enough to interfere with trial conduct (allowed if it is not the primary focus of treatment), MDD with current major depressive episode, or has required treatment within the 3 months prior to screening, or in investigator's opinion, MDD may worsen or could be expected to require treatment during the course of this trial.
  • Subjects who are breast-feeding and/or have a positive pregnancy test result prior to receiving IMP.
  • A significant risk of committing suicide based on history and the investigator's clinical judgment, or routine psychiatric status examination, current suicidal behavior, Imminent risk of injury to self, active suicidal ideation, history of suicidal behavior (over the last 6 months).
  • Body weight \< 13 kg
  • ≥ 40 kg/m2
  • Has initiated, changed, or discontinued receiving psychological interventions for ADHD within the 30 days before the screening visit, or are anticipated to start new treatment during the trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
680 participants (actual)

Study arms

  • Experimental
    Centanafadine Hydrochloride

    * Adolescents (13 to 17 years of age, inclusive) to receive 328.8 mg daily. * Children (4 to 12 years of age, inclusive) will receive weight-based doses of centanafadine ranging from 82.2 mg to 328.8 mg daily

    Drug: Centanafadine Hydrochloride

Interventions

  • DrugCentanafadine Hydrochloride

    Capsule

    Also known as: Centanafadine, Centanafadine XR, EB-1020

06

What researchers measure

Primary outcomes

  1. Frequency and severity of treatment-emergent adverse events (TEAEs) will be assessed to determine long-term safety and tolerability of Centanafadine QD XR Capsules.

    Time frame: Minimum duration of 52 weeks, up to a maximum of approximately 136 weeks or early termination.

07

Study locations

86 sites
  • Harmonex Neuroscience Research
    Dothan, Alabama 36303, United States
  • The Center for Clinical Trials, Inc.
    Saraland, Alabama 36571, United States
  • Southwest Autism Research and Resource Center
    Phoenix, Arizona 85006, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Care Access
    Beverly Hills, California 90212, United States
  • Proscience Research Group
    Culver City, California 90230, United States
  • Sun Valley Research Center, Inc.
    Imperial, California 92251, United States
  • Long Beach Clinical Trials Services, Inc
    Long Beach, California 90806, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • SDS Clinical Trials Inc
    Santa Ana, California 92705, United States
  • CMB Clinical Trials
    Santee, California 92071, United States
  • Pacific Clinical Research Management Group LLC
    Upland, California 91786, United States
  • MCB Clinical Research Centers
    Colorado Springs, Colorado 80910, United States
  • Mindscapes Counseling LLC DBA Comprehensive Psychiatric Care, PC
    Norwich, Connecticut 06360, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Reliable Clinical Research, LLC
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • West Broward Outpatient Site
    Lauderhill, Florida 33319, United States
  • Accel Research Sites - Maitland
    Maitland, Florida 32751, United States
  • Columbus Clinical Services, LLC
    Miami, Florida 33125, United States
  • Clinical Trials Solution
    Miami, Florida 33126, United States
  • Care Research Inc
    Miami, Florida 33130, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • ABRI
    Miami, Florida 33155, United States
  • Ivetmar Medical Group, LLC
    Miami, Florida 33155, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Florida International Research Center
    Miami, Florida 33173, United States
  • Anchor Medical Research, LLC
    Miami, Florida 33176, United States
  • RM Medical Research, Inc.
    Miami Lakes, Florida 33014, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Apg Research, Llc
    Orlando, Florida 32803, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Space Coast Neuropsychiatric Research Institute
    Palm Bay, Florida 32905, United States
  • University of South Florida, Psychiatry and Behavioral Neurosciences
    Tampa, Florida 33613, United States
  • Neuroscience Research Institute
    West Palm Beach, Florida 33407, United States
  • Atlanta Behavioral Research, LLC
    Atlanta, Georgia 30338, United States
  • CenExcel-iResearch, LLC
    Decatur, Georgia 30030, United States
  • Velocity Clinical Research Boise
    Meridian, Idaho 83642, United States
  • American Medical Research, Inc.
    Chicago, Illinois 60612, United States
  • AMR-Baber Research Inc
    Naperville, Illinois 60563, United States
  • Qualmedica Research
    Evansville, Indiana 47715, United States
  • Psychiatric Associates
    Overland Park, Kansas 66221, United States
  • Qualmedica Research LLC
    Bowling Green, Kentucky 42101, United States
  • Qualmedica Research, LLC
    Owensboro, Kentucky 42301, United States
  • Sisu BHR, LLC
    Springfield, Massachusetts 01103, United States
  • Neurobehavioral Medicine Group
    Bloomfield, Michigan 48302, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • St. Charles Psychiatric Associates / Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Alivation Research, LLC
    Lincoln, Nebraska 68526, United States
  • Vector Clinical Trials
    Las Vegas, Nevada 89128, United States
  • Albuquerque Neuroscience, INC
    Albuquerque, New Mexico 87109, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Manhattan Behavioral Medicine PLLC
    New York, New York 10036, United States
  • Onsite Clinical Solutions LLC
    Charlotte, North Carolina 28277, United States
  • University of Cincinnati Department of Psychiatry and Behavioral Neuroscience
    Cincinnati, Ohio 45219, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cincy Science
    West Chester, Ohio 45069, United States
  • IPS Research
    Oklahoma City, Oklahoma 73106, United States
  • SP Research, PLLC
    Oklahoma City, Oklahoma 73112, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Paradigm Research Professionals LLC
    Oklahoma City, Oklahoma 73118, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Velocity Clinical Research-Providence
    East Greenwich, Rhode Island 02818, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Clinical Neuroscience Solutions Inc.
    Memphis, Tennessee 38119, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • Inquest Clinical Research Baytown Health LLC
    Baytown, Texas 77521, United States
  • Houston Clinical Trials, LLC
    Bellaire, Texas 77401, United States
  • Javara Inc.
    Dallas, Texas 75230, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75231, United States
  • InSite Clinical Research, LLC
    DeSoto, Texas 75115, United States
  • Allure Health at Mt. Olympus Medical Research
    Friendswood, Texas 77546, United States
  • Synergy Groups Medical LLC
    Houston, Texas 77087, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • AIM Trials, LLC
    Plano, Texas 75093, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
  • Road Runner Research, Ltd.
    San Antonio, Texas 78249, United States
  • Family Psychiatry of The Woodlands
    The Woodlands, Texas 77381, United States
  • Velocity Clinical Research Salt Lake City
    West Jordan, Utah 84088, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Eastside Therapeutic Resource, Inc. dba Core Clinical Research
    Everett, Washington 98201, United States
  • Center for Pediatric Excellence
    Ottawa, Ontario K2G 1W2, Canada
  • Barbara Diaz Hernandez MD Research, Inc.
    San Juan, 00926, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Apr 2026, 50 months.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 50 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Mar 15, 2022
StartActual
Feb 24, 2022
Primary completionActual
Apr 24, 2026
CompletionActual
Apr 24, 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05279313
Responsible party
Sponsor
First posted
Mar 15, 2022
Start date
Feb 24, 2022
Primary completion
Apr 24, 2026
Completion
Apr 24, 2026
Last update
May 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion